Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

INTRODUCTION: Anti-PD-1 therapies, pembrolizumab and nivolumab, are currently the standard of care for treatment of patients with metastatic melanoma. Treatment is usually continued until toxicity or disease progression. Though these therapies are well tolerated, some patients discontinue them due t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Oncol
Main Authors: Swami, Umang, Monga, Varun, Bossler, Aaron D., Zakharia, Yousef, Milhem, Mohammed
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683789/
https://ncbi.nlm.nih.gov/pubmed/31428149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/1856594
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados